Back to mobile site

Cara Therapeutics (CARA) Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus Met Primary Endpoint

May 29, 2019 7:02 AM EDT Send to a Friend
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login